Ekso Bionics® Partners with HASOMED to Launch Functional Electrical Stimulation (FES) for the EksoGT™ Exoskeleton
December 14 2017 - 8:00AM
Ekso Bionics Holdings, Inc. (NASDAQ:EKSO), an industry leader in
exoskeleton technology for medical and industrial use, today
announced the launch of the EksoGT™ exoskeleton’s Functional
Electrical Stimulation (FES) interface capability through a
partnership with HASOMED, a developer of innovative products for
neurological rehabilitation. Previously used for research,
HASOMED’s RehaStim2 FES integration with EksoGT exoskeleton is now
CE Marked and available for routine clinical use in Europe.
“At Ekso Bionics, we strategically work to
improve patient outcome by continually revolutionizing
rehabilitation with our exoskeleton technology,” said Thomas Looby,
president and chief executive officer of Ekso Bionics. “The
combination of the EksoGT and its benefits, with the RehaStim2 FES
technology, provides clinicians with the latest advancements in
care, which ultimately improves clinical outcomes and patient
quality of life. The synergies between the two technologies mark an
important step in our ability to offer an even more versatile
device that enables clinicians to provide rehabilitation to a wider
range of patients across different disease states, including spinal
cord injuries and stroke.”
FES is a technique that uses low energy
electrical pulses to artificially generate body movements in
individuals who have been paralyzed due to injury to the central
nervous system. Clinical practitioners in EMEA can purchase
RehaStim2 through HASOMED, or as an upgrade, with training provided
by Ekso Bionics. The combination of exoskeleton technology with
FES, give clinicians the synergistic benefits of earlier mobility
and muscle stimulation to provide rehabilitation to a broader
spectrum of patients, ranging from pre-ambulatory to almost
independent.
“Our RehaStim2 FES device sends electrical
impulses to the muscles, generating targeted movement of
extremities despite paralysis,” commented Matthias Weber, chief
executive officer and owner of HASOMED. “Now, through our extended
partnership with Ekso Bionics, European rehabilitation specialists
will have the opportunity to provide cutting-edge combination
therapy to their patients.”
The first European customer installation for the
EksoGT exoskeleton with RehaStim2 FES device is slated for January
2018, and is currently available for investigational research use
in the United States.
For more information about Ekso Bionics or
EksoGT™, visit www.eksobionics.com.
About HASOMED GmbHHASOMED GmbH
is an owner-managed company focusing on neurological
rehabilitation. Originally established in 1991 in Kronberg /
Taunus, the head office was relocated in 1995 to Magdeburg. Dr.
Peter Weber and Matthias Weber are owners and CEOs of the company.
HASOMED GmbH are a spin-off from the Department of Science of the
Medical Faculty of the University Magdeburg. Thus the focus of
activities during first years of establishment was on development
and manufacturing of research technology.
About EksoGT™EksoGT™ is the
first exoskeleton cleared by the FDA for use with stroke and spinal
cord injuries from L5 to C7. The EksoGT with SmartAssist™ software
is the only exoskeleton available for rehabilitation institutions
that can provide adaptive amounts of power to either side of a
patient’s body, challenging the patient as they progress through
their continuum of care. The suit’s patented technology provides
the ability to mobilize patients earlier, more frequently, and with
a greater number of high intensity steps. To date, this device has
helped patients take more than 70 million steps in over 185
rehabilitation institutions around the world.
About Ekso Bionics®Ekso Bionics
is a leading developer of exoskeleton solutions that amplify human
potential by supporting or enhancing strength, endurance and
mobility across medical, industrial and defense applications.
Founded in 2005, the company continues to build upon its
unparalleled expertise to design some of the most cutting-edge,
innovative wearable robots available on the market. Ekso Bionics is
the only exoskeleton company to offer technologies that range from
helping those with paralysis to stand up and walk, to enhancing
human capabilities on job sites across the globe, to providing
research for the advancement of R&D projects intended to
benefit U.S. defense capabilities. The company is headquartered in
the Bay Area and is listed on the Nasdaq Capital Market under the
symbol EKSO. For more information, visit: www.eksobionics.com.
Forward-Looking StatementsAny
statements contained in this press release that do not describe
historical facts may constitute forward-looking statements.
Forward-looking statements may include, without limitation,
statements regarding (i) the ability to manage successfully and
complete the rights offering, (ii) the expected proceeds of the
offering, (iii) the anticipated use of proceeds from the offering,
if successful, and (iv) the assumptions underlying or relating to
any statement described in points (i), (ii) or (iii) above. Such
forward-looking statements are not meant to predict or guarantee
actual results, performance, events or circumstances and may not be
realized because they are based upon the Company's current
projections, plans, objectives, beliefs, expectations, estimates
and assumptions and are subject to a number of risks and
uncertainties and other influences, many of which the Company has
no control over. Actual results and the timing of certain events
and circumstances may differ materially from those described by the
forward-looking statements as a result of these risks and
uncertainties. Factors that may influence or contribute to the
inaccuracy of the forward-looking statements or cause actual
results to differ materially from expected or desired results may
include, without limitation, the Company's inability to obtain
adequate financing to fund the Company's operations and necessary
to develop or enhance our technology, the significant length of
time and resources associated with the development of the Company's
products, the Company's failure to achieve broad market acceptance
of the Company's products, the failure of our sales and marketing
organization or partners to market our products effectively,
adverse results in future clinical studies of the Company's medical
device products, the failure to obtain or maintain patent
protection for the Company's technology, failure to obtain or
maintain regulatory approval to market the Company's medical
devices, lack of product diversification, existing or increased
competition, and the Company's failure to implement the Company's
business plans or strategies. These and other factors are
identified and described in more detail in the Company's filings
with the SEC. To learn more about Ekso Bionics please visit us at
www.eksobionics.com. The Company does not undertake to update these
forward-looking statements.
Media Contact:Carrie
Yamond917-371-2320cyamond@lazarpartners.com
Investor Contact:Matthew
Ventimiglia212-599-1265investors@eksobionics.com
Ekso Bionics (NASDAQ:EKSO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ekso Bionics (NASDAQ:EKSO)
Historical Stock Chart
From Apr 2023 to Apr 2024